Department of Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Eur Arch Otorhinolaryngol. 2012 Apr;269(4):1073-83. doi: 10.1007/s00405-011-1831-4. Epub 2011 Nov 12.
Some laryngeal epithelial precursor lesions progress to invasive carcinoma and others do not. Routine light microscopic classification has limited value in predicting the evolution of these lesions. This article reviews the experience to date with the use of molecular markers for the prognostic evaluation of laryngeal epithelial precursor lesions. We conducted a thorough review of the published literature to identify those studies using biomarkers to predict malignant progression of laryngeal epithelial precursor lesions. Of the 336 studies identified in this systematic search, 15 met the inclusion criteria and form the basis of this review. Limited studies suggest that certain biomarkers are potentially reliable predictors of malignant progression including various regulators of cell adhesion and invasion (e.g. FAK, cortactin, osteopontin, and CD44v6) and proliferation-associated markers such as TGF-βRII and Kv3.4. The predictive value of these markers, however, has yet to be confirmed in large-scale prospective studies. Although the cell cycle-related proteins are the most frequently studied markers, none have been consistently reliable across multiple studies. The absence of standardization in methodologies, test interpretation, and other parameters may contribute to study inconsistencies. Various biomarkers have proved to have potential prognostic value and could be clinically relevant. The utility and prognostic power of these biomarkers should be confirmed in large, well-designed, standardized prospective studies.
一些喉上皮前体病变会进展为浸润性癌,而另一些则不会。常规的光镜分类在预测这些病变的演变方面价值有限。本文回顾了迄今为止使用分子标志物对喉上皮前体病变进行预后评估的经验。我们对已发表的文献进行了全面回顾,以确定那些使用生物标志物预测喉上皮前体病变恶性进展的研究。在这个系统搜索中确定了 336 项研究,其中 15 项符合纳入标准,构成了本综述的基础。有限的研究表明,某些生物标志物可能是恶性进展的可靠预测指标,包括各种细胞黏附和侵袭的调节剂(如 FAK、cortactin、骨桥蛋白和 CD44v6)和增殖相关标志物,如 TGF-βRII 和 Kv3.4。然而,这些标志物的预测价值尚未在大规模前瞻性研究中得到证实。尽管细胞周期相关蛋白是最常研究的标志物,但在多项研究中都没有一致性的可靠性。方法、测试解释和其他参数的标准化缺失可能导致研究不一致。各种生物标志物已被证明具有潜在的预后价值,并且可能具有临床相关性。这些生物标志物的实用性和预后价值应在大型、精心设计、标准化的前瞻性研究中得到证实。